| |
|
Annual
Revenue
Millions |
| 1981 |
The company is founded and CasChem group acquires the castor oil and derivatives product lines from NL Industries.
|
$ 38* |
| 1987 |
The Company name changes to Cambrex Corporation. Cambrex is listed on NASDAQ.
|
$108 |
| 1990 |
Cambrex is listed on the American Stock Exchange (AMEX).
|
$134 |
| 1991 |
The Company enters the life sciences arena with the acquisition of a company that produces animal feed additives and active pharmaceutical ingredients (APIs).
|
$145 |
| 1994 |
Cambrex further penetrates the pharmaceutical market with the acquisition of the Nobel Pharma Chemistry business.
|
$242 |
| 1997 |
Cambrex enters the biosciences market with the acquisition of a life sciences company providing cell culture and endotoxin detection products.
|
$382 |
| 1998 |
Cambrex acquires a chiral enzymatic catalyst business, a key pharmaceutical technology and a bioscience products facility in Belgium. The Company stock is listed on the NYSE.
|
$464 |
| 1999 |
Cambrex enters the growing fields of molecular biology and proteomics through the acquisition of FMC Corporation's bioproducts business and adds APIs and advanced intermediates capacity with the acquisition of a facility in Ireland.
|
$488 |
| 2000 |
The Cambrex Center of Technical Excellence opens, a new R&D facility to enable the company to leverage life sciences research capabilities in a single location. The company also acquires a Belgian manufacturer of APIs and pharmaceutical intermediates and adds a cell-based bioassay product line.
|
$492 |
| 2001 |
Cambrex enters the biologics market with the acquisition of two contract biopharmaceutical manufacturing facilities. The facilities produce purified bulk biologics and pharmaceutical ingredients from clinical to commercial scale.
|
$357** |
| 2002 |
To support the Company's strategic emphasis on the growing opportunities in the life sciences industry, Cambrex launches a new corporate identity.
|
$394** |
|
2003
2004
|
Cambrex completes the sale of Rutherford Chemicals. The company is dedicated to providing essential products and services that accelerate drug discovery, development and the manufacturing of human therapeutics.
John R. Leone joins Cambrex as President and Chief Executive Officer to succeed James A.Mack who is appointed Executive Chairman of the Board of Directors. Cambrex and Ortec International partner to market OrCel™ in the US. Cambrex also acquires Innovative Rapid Microbial Detection Company, Genolife.
|
$406**
$439**
|
| |
* Approximate annual revenue for 1982
** From continuing operations.
|
|
